See how top analysts and institutions rate DXCM — including buy, hold, and sell recommendations.
| Rating Source | Action | Rating | Target Price | Updated |
|---|---|---|---|---|
| Stifel | Resumed | Buy | $85 | 2025-10-21 |
| Oppenheimer | Downgrade | Outperform → Perform | 2025-09-08 | |
| Argus | Initiated | Buy | $100 | 2025-08-21 |
| Truist | Initiated | Buy | $102 | 2025-06-16 |
| Goldman | Initiated | Buy | $104 | 2025-05-30 |
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|
| November 2025 | 4 | 20 | 4 | 0 | 0 |
| October 2025 | 4 | 20 | 4 | 0 | 0 |
| September 2025 | 4 | 19 | 4 | 0 | 0 |
| August 2025 | 3 | 20 | 4 | 0 | 0 |
The majority of institutional investors have issued a "Buy" rating for DXCM, and analyst sentiment aligns closely, with very few "Sell" recommendations. This suggests a broadly favorable outlook for the stock's performance.
